The respiratory microbiota in lung cancer: bridging dysbiosis, immunomodulatory networks, and therapeutic opportunities
Advanced Cancer Research · 30.06.2026 · 1-29
DOI: 10.55092/acr20260009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Cancer Research, online erschienen am 30.06.2026. Verfasst von Yu Zhao und 1 weiteren Autor:innen.
Abstract (Originalsprache)
: Lung cancer remains the leading cause of cancer‑related mortality worldwide, with limited therapeutic responses and frequent acquired resistance. The respiratory microbiota has recently been recognized as an important regulator of lung cancer. Although most research has concentrated on the gut microbiota, its composition differs substantially from that of the lung microbiota. Emerging evidence indicates that dysbiosis of the airway and intratumoral microbiome contributes to lung oncogenesis, disease progression
Zitieren
APA
Zhao, Y., & Li, S. (2026). The respiratory microbiota in lung cancer: bridging dysbiosis, immunomodulatory networks, and therapeutic opportunities. Advanced Cancer Research, 1-29. https://doi.org/10.55092/acr20260009
Vancouver
Zhao Y, Li S. The respiratory microbiota in lung cancer: bridging dysbiosis, immunomodulatory networks, and therapeutic opportunities. Advanced Cancer Research. 2026:1-29. doi:10.55092/acr20260009
BibTeX
@article{Zhao2026,
author = {Zhao, Yu and Li, Shengqing},
title = {The respiratory microbiota in lung cancer: bridging dysbiosis, immunomodulatory networks, and therapeutic opportunities},
journal = {Advanced Cancer Research},
year = {2026},
pages = {1--29},
doi = {10.55092/acr20260009}
}
EUVIMED